[Research Advances on Transformation to Small Cell Lung Cancer]

Area of Science:

• Oncology
• Molecular Biology
• Translational Medicine

Background:

• Transformation to small cell lung cancer (SCLC) is a key resistance mechanism in non-small cell lung cancer (NSCLC), especially in EGFR-mutant lung adenocarcinoma.
• Translational SCLC exhibits clinical characteristics similar to primary SCLC, posing significant therapeutic challenges.

Purpose of the Study:

• To review current research on the clinical features, molecular mechanisms, and treatment options for SCLC transformation in NSCLC.
• To provide an overview of the challenges and advancements in managing this specific lung cancer subtype.

Main Methods:

• Literature review of studies on SCLC transformation in NSCLC.
• Analysis of clinical data, molecular alterations (e.g., RB1 deletion), and treatment outcomes.

Main Results:

• Chemotherapy offers short-term efficacy for transformational SCLC, with a median survival of approximately one year.
• RB1 deletion and somatic copy number alterations are associated with SCLC transformation, though underlying mechanisms require further elucidation.

Conclusions:

• Transformational SCLC presents significant treatment hurdles, with SCLC chemotherapy regimens being the primary approach.
• Combination therapies, local treatments, and preventative strategies are under investigation to improve outcomes for patients with transformational SCLC.